WO2001025438A3 - Ifn-alpha homologues - Google Patents

Ifn-alpha homologues Download PDF

Info

Publication number
WO2001025438A3
WO2001025438A3 PCT/US2000/027781 US0027781W WO0125438A3 WO 2001025438 A3 WO2001025438 A3 WO 2001025438A3 US 0027781 W US0027781 W US 0027781W WO 0125438 A3 WO0125438 A3 WO 0125438A3
Authority
WO
WIPO (PCT)
Prior art keywords
homologues
nucleic acids
polypeptides
ifn
methods
Prior art date
Application number
PCT/US2000/027781
Other languages
French (fr)
Other versions
WO2001025438A2 (en
Inventor
Volker Heinrichs
Teddy Chen
Phillip A Patten
Original Assignee
Maxygen Inc
Volker Heinrichs
Teddy Chen
Phillip A Patten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc, Volker Heinrichs, Teddy Chen, Phillip A Patten filed Critical Maxygen Inc
Priority to JP2001528590A priority Critical patent/JP2003511031A/en
Priority to MXPA02003492A priority patent/MXPA02003492A/en
Priority to CA002385045A priority patent/CA2385045A1/en
Priority to AU80013/00A priority patent/AU8001300A/en
Priority to EP00970665A priority patent/EP1238082A2/en
Publication of WO2001025438A2 publication Critical patent/WO2001025438A2/en
Publication of WO2001025438A3 publication Critical patent/WO2001025438A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Alpha interferon homologues (both nucleic acids and polypeptides) are provided. Compositions including these interferon homologue polypeptides and nucleic acids, recombinant cells comprising said homologue polypeptides and nucleic acids, methods of making the new homologues, antibodies to the new homologues, and methods of using the homologues are provided. Integrated systems comprising the sequences of the nucleic acids or polypeptides are also provided.
PCT/US2000/027781 1999-10-07 2000-10-06 Ifn-alpha homologues WO2001025438A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001528590A JP2003511031A (en) 1999-10-07 2000-10-06 IFN-α homolog
MXPA02003492A MXPA02003492A (en) 1999-10-07 2000-10-06 Ifn alpha homologues.
CA002385045A CA2385045A1 (en) 1999-10-07 2000-10-06 Ifn-alpha homologues
AU80013/00A AU8001300A (en) 1999-10-07 2000-10-06 Ifn-alpha homologues
EP00970665A EP1238082A2 (en) 1999-10-07 2000-10-06 Ifn-alpha homologues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41518399A 1999-10-07 1999-10-07
US09/415,183 1999-10-07

Publications (2)

Publication Number Publication Date
WO2001025438A2 WO2001025438A2 (en) 2001-04-12
WO2001025438A3 true WO2001025438A3 (en) 2002-07-11

Family

ID=23644696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027781 WO2001025438A2 (en) 1999-10-07 2000-10-06 Ifn-alpha homologues

Country Status (8)

Country Link
EP (1) EP1238082A2 (en)
JP (1) JP2003511031A (en)
CN (1) CN1451045A (en)
AR (1) AR025969A1 (en)
AU (1) AU8001300A (en)
CA (1) CA2385045A1 (en)
MX (1) MXPA02003492A (en)
WO (1) WO2001025438A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521216B2 (en) 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
FR2822845B1 (en) * 2001-03-30 2003-12-12 Genodyssee NOVEL POLYNUCLEOTIDES COMPRISING FUNCTIONAL SNP-LIKE POLYMORPHISMS IN THE NUCLEOTIDE SEQUENCE OF THE IFN-ALPHA-21 GENE AS WELL AS NEW POLYPEPTIDES ENCODED BY THESE POLYNUCLEOTIDES AND THEIR THERAPEUTIC USES
FR2823763A1 (en) * 2001-04-18 2002-10-25 Genodyssee New polynucleotides and polypeptides of interferon alpha-6 gene comprising at least one single nucleotide polymorphism, useful for preventing or treating e.g. cancer, asthma, allergies, psoriasis, AIDS or Parkinson's disease
FR2823764B1 (en) 2001-04-24 2003-12-12 Genodyssee NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFN ALPHA-17 GENE
FR2824333B1 (en) 2001-05-03 2003-08-08 Genodyssee NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF IFN ALPHA 5
FR2825716B1 (en) * 2001-06-11 2004-09-24 Genodyssee NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES FROM IFN ALPHA 7
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US7932064B2 (en) 2002-06-13 2011-04-26 Verenium Corporation Processes for making (R)-ethyl 4-cyano-3-hydroxybutyric acid
US7611700B2 (en) 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
KR20050086498A (en) * 2002-11-18 2005-08-30 맥시겐, 인크. Interferon-alpha polypeptides and conjugates
JP2008507298A (en) 2004-05-19 2008-03-13 マキシジェン， インコーポレイテッド Interferon alpha polypeptides and conjugates
MX2007014524A (en) 2005-05-18 2008-02-07 Maxygen Inc Evolved interferon-alpha polypeptides.
EP2115153B1 (en) 2007-03-01 2013-06-05 BP Corporation North America Inc. Nitrilases, nucleic acids encoding them and methods for making and using them
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002457A1 (en) * 1982-01-15 1983-07-21 Cetus Corp Interferon-alpha 76
WO2000052153A2 (en) * 1999-03-02 2000-09-08 Maxygen, Inc. Method to identify ligands for orphan receptors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801685A (en) * 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002457A1 (en) * 1982-01-15 1983-07-21 Cetus Corp Interferon-alpha 76
WO2000052153A2 (en) * 1999-03-02 2000-09-08 Maxygen, Inc. Method to identify ligands for orphan receptors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHANG C -C J ET AL: "EVOLUTION OF A CYTOKINE USING DNA FAMILY SHUFFLING", NATURE BIOTECHNOLOGY,NATURE PUBLISHING,US, vol. 17, no. 8, August 1999 (1999-08-01), pages 793 - 797, XP000946490, ISSN: 1087-0156 *
CRAMERI A ET AL: "DNA SHUFFLING OF A FAMILY OF GENES FROM DIVERSE SPECIES ACCELERATESDIRECTED EVOLUTION", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 391, 15 January 1998 (1998-01-15), pages 288 - 291, XP000775869, ISSN: 0028-0836 *
D.V. GOEDDEL ET AL: "The stucture of eight distinct cloned human leukocyte interferon cDNAs", NATURE, vol. 290, no. 5, 5 March 1981 (1981-03-05), pages 20 - 26, XP002055149 *
DATABASE EMBL 26 November 1990 (1990-11-26), E. GREN ET AL: "human leukocyte interferon-alpha mRNA, complete cds, clone pIFN9", XP002176121 *
E. GREN ET AL: "Novel leukocyte interferon subtype and structural comparison of alpha interferon genes", JOURNAL OF INTERFERON RESEARCH, vol. 4, 1984, pages 609 - 617, XP001016190 *
HENCO K ET AL: "STRUCTURAL RELATIONSHIP OF HUMAN INTERFERON ALPHA GENES AND PSEUDOGENES", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 185, no. 2, 20 September 1985 (1985-09-20), pages 227 - 260, XP000605295, ISSN: 0022-2836 *
SCAROZZA A M ET AL: "DNA SYNTHESIS IN NUCLEI ISOLATED FROM DAUDI B CELLS: A MODEL TO STUDY THE ANTIPROLIFERATIVE MECHANISMS OF INTERFERON-ALPHA", JOURNAL OF INTERFERON RESEARCH, MARY ANN LIEBERT, INC., NEW YORK, NY, US, vol. 12, 1992, pages 35 - 42, XP001002244, ISSN: 0197-8357 *

Also Published As

Publication number Publication date
AU8001300A (en) 2001-05-10
CA2385045A1 (en) 2001-04-12
JP2003511031A (en) 2003-03-25
EP1238082A2 (en) 2002-09-11
CN1451045A (en) 2003-10-22
MXPA02003492A (en) 2002-08-20
WO2001025438A2 (en) 2001-04-12
AR025969A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
WO2001025438A3 (en) Ifn-alpha homologues
WO2001075087A3 (en) Subtilisin variants
WO2000023472A3 (en) Interferon-beta fusion proteins and uses
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
EP1260587A3 (en) Tyrosyl tRNA synthetase
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
WO1999031236A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
WO2002006457A3 (en) Novel lipase genes
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
WO1998058957A3 (en) Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
WO1999013075A3 (en) Human genes regulated by human cytomegalovirus and interferon
WO2001019870A3 (en) Secreted soluble alpha2delta-2, alpha2delta-3, alpha2delta-4 calcium channel subunit polypeptides and screening assays using same
WO1999022005A3 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
EP0897011A3 (en) Novel arginine deiminase
WO2001040257A3 (en) Modified il-12 subunits and nucleic acids encoding them
DK0665890T3 (en) Increased production of secreted proteins by recombinant eukaryotic cells
WO2001064912A3 (en) Triazine degrading enzymes
AU1141695A (en) Interferon-alpha/beta binding protein, its preparation and use
WO2002062964A3 (en) Ap1 amine oxidase variants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2385045

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 80013/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003492

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 528590

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/643/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000970665

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008167133

Country of ref document: CN

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000970665

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000970665

Country of ref document: EP